Breaking News, Financial News

Financial Report: Mylan

Specialty segment sales up 24% in the quarter

Mylan

1Q Revenues: $1.6 billion (+3%)
 
1Q Earnings: $107.5 million (-17%)
 
Comments: Third party revenues from Mylan’s Generics segment were $1.4 billion, up 2%. North America revenues were $732.8 million, up 5%. EMEA revenues were $369.9 million, up 10%. Asia Pacific revenues were $305.1 million, up 2%. Mylan’s Specialty segment sales were $211.6 million, up 24% driven by EPIPEN Auto-Injector. Earnings include expenses related to R&D licensing payments of $23 million and acquisition related costs of $19 million.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters